864825-81-0 Usage
Description
4-BROMO-3,5-DIMETHYL-BENZAMIDE is an organic compound that serves as an intermediate in the synthesis of imidazole derivatives. It is characterized by the presence of a bromo group at the 4-position, and methyl groups at the 3 and 5 positions on a benzene ring, with an amide functional group attached.
Uses
Used in Pharmaceutical Industry:
4-BROMO-3,5-DIMETHYL-BENZAMIDE is used as a chemical intermediate for the preparation of imidazole derivatives, which are known as opioid receptor modulators. These modulators have potential applications in the development of medications for pain management and treatment of opioid-related disorders, due to their ability to interact with opioid receptors in the central nervous system.
Check Digit Verification of cas no
The CAS Registry Mumber 864825-81-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,6,4,8,2 and 5 respectively; the second part has 2 digits, 8 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 864825-81:
(8*8)+(7*6)+(6*4)+(5*8)+(4*2)+(3*5)+(2*8)+(1*1)=210
210 % 10 = 0
So 864825-81-0 is a valid CAS Registry Number.
InChI:InChI=1/C9H10BrNO/c1-5-3-7(9(11)12)4-6(2)8(5)10/h3-4H,1-2H3,(H2,11,12)
864825-81-0Relevant articles and documents
ANTIDIABETIC TRICYCLIC COMPOUNDS
-
Page/Page column 115, (2015/06/03)
Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.
NOVEL COMPOUNDS AS OPIOID RECEPTOR MODULATORS
-
Page/Page column 45, (2010/02/13)
The present invention is directed to novel opioid receptor modulators of Formula (I). The invention further relates to methods for preparing such compounds, pharmaceutical compositions containing them, and their use in the treatment of disorders that may